<DOC>
	<DOCNO>NCT02677688</DOCNO>
	<brief_summary>EBV implicate pathogeny SLE increase EBV sero-prevalence , defective control EBV infection alter B T immune response virus The main objective pilot proof-of-concept ( POC ) study evaluate safety efficacy autologous EBV specific CTL adoptive transfer adult patient serologically active SLE</brief_summary>
	<brief_title>Autologous EBV-specific Cytotoxic T Cells Treatment Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>Systemic lupus disable disease young woman , whose treatment base long-term corticosteroid , anti-malarials immunosuppressant synthesis . This support without potential side effect . EBV herpes cause infectious mononucleosis virus , usually encounter childhood adolescence , natural immunity cell ( CD8 T cell ) control life , eliminate . Increasingly scientific study show patient systemic lupus ( multiple sclerosis ) , failure self-control EBV virus , T lymphocytes ( CD8 ) . This uncontrolled virus stimulate B lymphocytes , produce antibody , toxic lupus . The laboratory isolate T cell specific EBV ( EBV-CTL ) patient , stimulate culture strengthen . They re-injected single intravenous infusion ( autotransfusion ) , use control virus certain disease EBV demonstrate role post-transplant lymphoproliferative disorder , chronic fatigue syndrome EBV-induced . Our therapeutic approach completely innovative , base principle cell therapy , thus use new drug , base restoration patient 's immune system , specific EBV .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>4 systemic lupus criterion American College Rheumatology antinuclear antibody &gt; 1:80 Age great equal 18 year Lupus serologically active without active serious disease ( Kidney , CNS ) Antinative DNA Ac positive / C3 C4 low SLEDAI great equal 2 baseline Serology HBV , HCV , HIV , HTLV1 , syphilis : Negative J30 sample Blood lymphocytes &gt; 750 / mm3 Prednisone dose &lt; 15 mg / day stable dose within 30 day previous injection Immunosuppressive treatment dosage increase least 3 month enrollment Agreement telephone / mail coordinate investigator inclusion Social ensure Patient EBV positive serology Evolving severe lupus , require high dose corticosteroid / immunosuppressive therapy Psychiatric disorder Predicted Failure monitor compliance impossibility Infectious Episode underway Evolutionary Cancer Risk death within 6 month Consent Refusal Pregnancy Nursing woman Elderly patient 65 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>autologous anti-EBV CTL</keyword>
	<keyword>adoptive therapy</keyword>
	<keyword>phase 1 -2</keyword>
</DOC>